Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Johnson & Johnson (JNJ) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) - $25 value - yours FREE >>
Image: Bigstock
Geron (GERN) Gets Three Patents for Imetelstat in the U.S.
Geron Corporation (GERN - Free Report) announced the issuance of three U.S. patents related to its telomerase inhibitor, imetelstat.
The first patent (U.S. Patent No. 9,375,485) covers imetelstat’s use for alleviating at least one symptom of myelofibrosis or myelodysplastic syndromes, including chronic myelomonocytic leukemia.
The other two patents (U.S. Patent No. 9,388,415 and U.S. Patent No. 9,388,416) are related to the methods of using imetelstat to inhibit the activity of telomerase as well as to inhibit cancer cell proliferation. They also include methods for using imetelstat to treat cancer.
The first patent is expected to be valid till at least Mar 2033, while the other two will run through at least Sept 2024.
GERON CORP Price
GERON CORP Price | GERON CORP Quote
These patents relate to Geron’s existing patent (U.S. Patent No. 7,494,982) on imetelstat’s composition of matter, which was issued in 2009 and is expected to be valid until at least Dec 2025.
Geron has licensed its portfolio of patents related to imetelstat to Janssen Biotech, a Johnson & Johnson (JNJ - Free Report) company. In Nov 2014, Geron entered into a license and collaboration agreement under which Janssen was granted exclusive worldwide rights to develop and commercialize imetelstat for all human therapeutic uses, including hematologic myeloid malignancies.
Currently, Janssen is conducting two studies on imetelstat – IMbark (phase II) for the treatment of myelofibrosis and IMerge (phase II/III) for the treatment of myelodysplastic syndromes.
Currently, Geron carries a Zacks Rank #3 (Hold). Johnson & Johnson is a better-ranked stock with a Zacks Rank #2 (Buy). Other favorably ranked stocks in the health care sector include GW Pharmaceuticals plc and Innoviva, Inc. (INVA - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>